Viking Historical Income Statement
| VKTX Stock | USD 52.94 1.57 2.88% |
Historical analysis of Viking Therapeutics income statement accounts such as Depreciation And Amortization of 277.4 K, Interest Expense of 83.6 K, Selling General Administrative of 38.9 M or Other Operating Expenses of 105.9 M can show how well Viking Therapeutics performed in making a profits. Evaluating Viking Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Viking Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Viking Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Viking Therapeutics is a good buy for the upcoming year.
Viking |
About Viking Income Statement Analysis
Viking Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Viking Therapeutics shareholders. The income statement also shows Viking investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Viking Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Viking Therapeutics. It is also known as Viking Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Viking Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Viking Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viking Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.At this time, Viking Therapeutics' Selling General Administrative is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 105.9 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 277.4 K in 2024.
Viking Therapeutics income statement Correlations
Click cells to compare fundamentals
Viking Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Viking Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 7.2M | 3.8M | 296K | 291K | 292K | 277.4K | |
| Interest Expense | 146K | 106K | 18K | 1.5M | 88K | 83.6K | |
| Selling General Administrative | 9.1M | 10.7M | 10.7M | 16.1M | 37.0M | 38.9M | |
| Other Operating Expenses | 32.7M | 42.7M | 55.7M | 70.4M | 100.8M | 105.9M | |
| Operating Income | (32.7M) | (42.7M) | (55.7M) | (70.4M) | (100.8M) | (95.8M) | |
| Ebit | (32.7M) | (39.5M) | (55.7M) | (70.6M) | (100.8M) | (95.8M) | |
| Research Development | 23.6M | 31.9M | 45.0M | 54.2M | 63.8M | 67.0M | |
| Ebitda | (25.5M) | 3.8M | (55.4M) | (70.4M) | (100.8M) | (95.8M) | |
| Total Operating Expenses | 32.7M | 42.7M | 55.7M | 70.4M | 100.8M | 105.9M | |
| Income Before Tax | (25.8M) | (39.5M) | (55.0M) | (68.9M) | (85.9M) | (81.6M) | |
| Total Other Income Expense Net | 6.9M | 42.6M | 692K | 1.5M | 14.9M | 15.7M | |
| Net Income | (25.8M) | (39.5M) | (54.0M) | (67.4M) | (85.9M) | (81.6M) | |
| Income Tax Expense | (4K) | (3.5M) | (988K) | (1.5M) | (292K) | (306.6K) | |
| Gross Profit | (260K) | 10.7K | (296K) | (291K) | (292K) | (277.4K) | |
| Net Income From Continuing Ops | (25.8M) | (39.5M) | (55.0M) | (69.1M) | (80.8M) | (76.8M) | |
| Cost Of Revenue | 260K | 277K | 296K | 291K | 292K | 155.8K | |
| Net Income Applicable To Common Shares | (25.8M) | (39.5M) | (55.0M) | (68.9M) | (62.0M) | (58.9M) | |
| Interest Income | 7.1M | 3.2M | 703K | 1.6M | 11.0M | 11.6M | |
| Non Operating Income Net Other | 6.9M | 3.2M | 692K | 1.2M | 1.4M | 1.5M | |
| Net Interest Income | 6.9M | 3.1M | 685K | 1.5M | 11.0M | 11.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.